Introduction GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have revolutionized weight management and type 2 diabetes treatment, helping over 1.6 million adults in England, Wales, and Scotland between early 2024 and early 2025
This table shows how many weekly doses each vial size provides at standard tirzepatide titration doses
In markets such as the US, the question of health coverage also becomes a critical factor
Early studies explore safety, dose ranges, and biological effects
Television host and producer Andy Cohen has candidly revealed his use of GLP-1 weight loss medication, marking another high-profile celebrity discussion about these increasingly popular drugs
Nutr Metab Cardiovasc Dis 2022;32:2279-2288